Contact Information: Contact Information US Investors: Andrea Costa Grayling Global (646) 284-9461 acosta@hfgcg.com Company: Mark Diamond Managing Director +61 3 9827 8999
Antisense Therapeutics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
| Source: Antisense Therapeutics
MELBOURNE, AUSTRALIA--(Marketwire - October 27, 2008) - Antisense Therapeutics Limited (ASX : ANP ) today announced that the Company is scheduled to present at the Rodman
& Renshaw 10th Annual Global Healthcare Conference, on November 10-12, at
the New York Palace Hotel in New York City.
Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a
presentation on November 12, at 12:25 p.m. EST on the Company's drug
development pipeline, and the recent completion of a successful Phase IIa
clinical trial with its lead compound, ATL1102, which has been licensed to
Teva Pharmaceutical Industries (Teva). The presentation will be followed
by a question and answer session and a live webcast may be accessed at the
Company's website, www.antisense.com.au.
A replay of the presentation will be archived for 90 days after the
conference, at the same location. For more information about the Rodman &
Renshaw 10th Annual Healthcare Conference, please visit Rodman & Renshaw's
website at www.rodmanandrenshaw.com.
Antisense management will be available for meetings in New York on November
11-14.
In September, the results from the ATL/TV1102 Phase IIa clinical trial in
patients with MS were presented at the World Congress on Treatment and
Research in Multiple Sclerosis in Montreal, Canada by the Principal
Investigator for the trial, Volker Limmroth, M.D., Ph.D., Chairman of the
Department of Neurology, Cologne City Hospitals, Germany.
In the study, it was demonstrated that ATL/TV1102, a second-generation
antisense drug designed to specifically inhibit the production of VLA-4 (a
clinically validated target in MS), significantly reduced the number of new
active lesions in patients with Relapsing Remitting MS taking ATL/TV1102
for 8 weeks. The development of ATL/TV1102 as an MS treatment continues
with ANP's licensing partner Teva.
Earlier this month, the Company reported positive results from its
collaborative preclinical research study on the therapeutic potential of
ATL1101 in prostate cancer. ATL1101 is a second-generation antisense
inhibitor of the insulin-like growth factor-I receptor (IGF-IR), which has
previously shown potent activity in laboratory studies, including in human
cancer cells.
The key findings from the research study were that ATL1101 injections
significantly suppressed the growth of the human prostate tumors and slowed
down their transition to the most dangerous form of prostate cancer,
castration-resistant prostate cancer. These results were presented at New
York Academy of Sciences Annual Meeting of the Oligonucleotide Therapeutics
Society, Harvard Conference Center in Boston.
About Antisense Therapeutics Limited: Antisense Therapeutics Limited (ASX : ANP ) is an Australian publicly listed biopharmaceutical drug discovery and
development company. Its mission is to create, develop and commercialize
antisense pharmaceuticals for large unmet markets. ANP has two drugs in
development and two drugs in pre-clinical research. ATL/TV1102 (injection)
has completed a Phase IIa trial as a potential treatment of multiple
sclerosis. ATL1103 is a second-generation antisense drug designed to lower
blood IGF-I levels and is entering pre-clinical development as a potential
treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at
the pre-clinical research stage as a potential treatment for asthma.
ATL1101 is a second-generation antisense drug at the pre-clinical research
stage being investigated as a potential treatment for prostate cancer.
ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd.
Website: www.antisense.com.au